Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment
Condition: Non-valvular Atrial Fibrillation Intervention: Drug: Rivaroxaban (Xarelto, BAY59-7939) Sponsors: Bayer; Janssen Research & Development, LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Atrial Fibrillation | Cardiology | Heart | Heart Valve Disease | Heart Valves | Italy Health | Research | Study